Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).

Demirci U, Tufan G, Aktas B, Balakan O, Alacacioglu A, Dane F, Engin H, Kaplan MA, Gunaydin Y, Ozdemir NY, Tugba Unek I, Karaca H, Akman T, Sonmez OU, Coskun U, Harputluoglu H, Sevinc A, Tonyali O, Buyukberber S, Benekli M.

Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO). J Cancer Res Clin Oncol.

2013 May;139(5):829-35. doi: 10.1007/s00432-013-1390-8. Epub 2013 Feb 12. PubMed PMID: 23400732.